InMed Pharmaceuticals Inc. · NASDAQ:INM
InMed Pharmaceuticals — Investor Presentation (November 2024)
24 slides from InMed Pharmaceuticals's investor presentation, November 2024
Slide 1: Corporate Presentation
Corporate Presentation November 2024 :INM www.inmedpharma.com
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements and forward-looking information within the meaning of applicable securities laws (collectively, “forward-looking statements”) including, among others, statements concerning: anticipated development activities, timelines
Slide 3: Overview & Investment Highlights
Overview & Investment Highlights • Robust R&D pipeline with 3 candidates in dermatology, ocular and Alzheimer’s • A successful Phase 2 dermatology program, currently seeking partnerships • Library of proprietary analogs targeting diverse pharmaceutical applications • A revenue generating subsidiary
Slide 4: A Clinical Stage Pharmaceutical Company
A Clinical Stage Pharmaceutical Company A GLOBAL LEADER IN THE RESEARCH, DEVELOPMENT, MANUFACTURING AND COMMERCIALIZATION OF RARE CANNABINOIDS Drug Discovery Pharmaceutical R&D Manufacturing Commercial • Pipeline of pharmaceutical programs • Screening of therapeutic • Chemical and • B2B supplier to
Slide 5: Drug Development Programs
Drug Development Programs
Slide 6: Pharmaceutical Pipeline: Small Molecules Targeting CB1/CB2
Pharmaceutical Pipeline: Small Molecules Targeting CB1/CB2 HIGHLIGHTS SCREENING PRECLINICAL PH 1 PH 2 PH 3 • In vivo studies – improved neuronal INM-9 01 CBx function, neuroprotection, other beneficial Alzheimer’s disease effects • Patent application filed INM-0 89 CBN • Planning for IND-enabling to
Slide 7: Alzheimer's Disease – A Major Medical & Societal Burden
Alzheimer’s Disease – A Major Medical & Societal Burden CURRENT TREATMENT OPTIONS DO NOT REVERSE EFFECTS What is Alzheimer’s Disease? Impact Alzheimer's is a subset of dementia that impacts • Alzheimer’s accounts for 60-80% the part of the brain that controls thought, memory of dementia cases and la
Slide 8: INM-901: A Multi-factorial Approach
INM-901: A Multi-factorial Approach POTENTIALLY DISEASE-MODIFYING SMALL MOCECULE DRUG CANDIDATE A preferential signaling Oral formulation that can agonist for CB1/CB2 and safely pass the blood/brain impacts PPAR signaling barrier pathways Increased neurite Improved behavior and outgrowth in in vitro
Slide 9: INM-901: Potential Multiple Mechanisms of Action
INM-901: Potential Multiple Mechanisms of Action INM-901 INM-901 Cytotoxicity • Proprietary small Neuroinflammation molecule compound can cross BBB Neuroprotection • Can be formulated Neurite outgrowth orally Neuronal function • Preferential signaling Locomotion agonist for CB1/CB2 Memory • Impacts
Slide 10: INM-901 Long-term Preclinical Studies Confirm Earlier Study Data
INM-900 Series in ALZ INM-901 Long-term Preclinical Studies Confirm Earlier Study Data Study Design • 7-month of dosing, in vivo INM-901 Results • Confirmed improvements in cognitive • 5xFAD amyloidosis model function, memory and locomotor activity • Extended dosing duration and increased • Achieved
Slide 11: INM-901 Summary
INM-901 Summary Next steps Research & Development • Small molecule, systemic delivery across the BBB • Additional molecular analysis long- • Possibly deliverable via oral ingestion term studies ongoing • Planning study in • In vitro: Demonstrates 2 distinct features neuroinflammation model • Neuropr
Slide 12: Impact of Dry Age-related Macular Degeneration (AMD)
Impact of Dry Age-related Macular Degeneration (AMD) LEADING CAUSE OF VISION LOSS What is AMD? AMD Opportunity AMD is an eye disease that can blur your • Affects 19.8M Americans central vision, eventually leading to loss aged 40+ of vision. It happens when aging causes • 12.6% of the U.S. population
Slide 13: AMD Occurs When the Macula is Damaged
AMD Occurs When the Macula is Damaged Back of eye Retina Retina (Macular Area) Damaged Photoreceptor macula at the cells back of the eye Retinal Pigment Epithelium Choroid Age-related Optic Macular Nerve Degeneration Dry AMD is the most common form of AMD. In the advanced stages of dry AMD, called G
Slide 14: INM-089: A Differentiated Approach to Treating Dry AMD
INM-089: A Differentiated Approach to Treating Dry AMD A preferential signaling Ability to proactively protect ligand for CB1 and CB2 the retinal ganglion cells Demonstrated promise Improved the thickness in preserving retinal of the outer nuclear layer function in an INM-089 of the retina where the
Slide 15: INM-089 Summary
INM-089 Summary Next steps Research & Development • Proprietary small molecule drug candidate • On-going dose-ranging studies • Deliverable via IVT formulation • Continuing CMC activities for drug substance and drug product • In vitro: Demonstrates Neuroprotection of RGC via • On-going studies of re
Slide 16: INM-755 Cannabinol (CBN) Cream: Phase 2 Results in Itch
INM-755 Cannabinol (CBN) Cream: Phase 2 Results in Itch Conducted in Epidermolysis bullosa patients – a severe genetic dermatological disease with chronic, severe itch as a primary symptom. Key Results: Non-Wound Itch: Data breakdown Of the 18 participants assessed, chronic itch improved by a • A po
Slide 17: BayMedica Commercial Business
BayMedica Commercial Business
Slide 18: BayMedica - Wholesale Rare Cannabinoids for the H&W Market
BayMedica -Wholesale Rare Cannabinoids for the H&W Market HIGH PURITY, CONSISTENT & BIOIDENTICAL TO NATURE CBC CBDV THCV CBT Cannabichromene Cannabidivarin Tetrahydrocannabivarin Cannabicitran CONS IS TENC Y COST - EFFECTI VEN ESS High quality, bioidentical rare cannabinoids with exceptional Multipl
Slide 19: BayMedica Financial Performance
BayMedica Financial Performance Calendar Year Revenue Growth US$ (Fiscal year ends June 30) (000’s) 2,500 $2.3M • Trailing 12-month revenue is $4.9m 2,000 • Currently operating as a cash flow positive business 1,500 • $300K net income in 3Q24 $1.3M $1.3M $1.2M $1.2M 1,000 $1M $895K • Forecasting imp
Slide 20: Corporate
Corporate
Slide 21: Depth in Pharmaceutical R&D
Depth in Pharmaceutical R&D EXTENSIVE EXPERIENCE IN PHARMA DISCOVERY, DEVELOPMENT, API MANUFACTURING, CLINICAL AND REGULATORY Eric A. Adams, MIBS Neeta Jagpal, CPA Michael Woudenberg, PEng Jerry P. Griffin Shane Johnson, MD Chief Executive Officer Chief Financial Officer Chief Operating Officer VP ,
Slide 22: Fiscal 2024 – Key Value Drivers
Fiscal 2024 – Key Value Drivers • Advance INM-901 in ALZ in long-term preclinical in vivo studies and manufacturing • Advance INM-089 in Dry AMD towards IND filing / human clinical trials • Evaluate INM-755 in itch for clinical and commercial partnerships • Target proprietary cannabinoid analogs for
Slide 23: Financial Snapshot
Financial Snapshot As of 2024-11-22 Cash and Short-term Investments $5.6 M(1) Shares I/O 725 K Options 33 K Warrants and Preferred Investment Options (478k @$16.6) 598 K Fully Diluted Shares 1.36 M Close $4.67 52-week High $15.6 52-week Low $2.4 Avg. Daily Volume (Trailing 50 Days) 40.7 K Market Cap
Slide 24: Thank you!
Thank you! Colin Clancy Vice President, Investor Relations & Corporate Communications [email protected] +1-604-416-0999 :INM www.inmedpharma.com
InMed Pharmaceuticals — Investor Presentation (November 2024) on 6ix